61st American Society of Hematology annual meeting in Orlando, Fla. – Dec. 7-10, 2019
|Ascentage Pharma Group International, of Suzhou, China||HQP-1351||BCR-ABL inhibitor||Tyrosine kinase inhibitor-resistant chronic myeloid leukemia||In a phase I study, complete hematologic response rate was 95% in 87 patients in the chronic phase (CP) and 85% in 14 patients in the accelerated phase (AP); major molecular response rate was 37% in CP and 36% in AP|
|Geron Corp., of Menlo Park, Calif.||Imetelstat||Telomerase inhibitor||Non-del(5q) lower-risk myelodysplastic syndromes||Of the 38 evaluable patients from the phase II Imerge study, 42% achieved ≥8-week red blood cell-transfusion independence (RBC-TI) and 28% achieved ≥24-week RBC-TI; median duration of TI was 85.9 weeks|
|Geron Corp., of Menlo Park, Calif.||Imetelstat||Telomerase inhibitor||Preclinical (myelofibrosis)||Treatment of malignant myelofibrosis cells with JAK inhibitor Jakafi (ruxolitinib, Incyte Corp.) followed by imetelstat produced a greater reduction in malignant progenitor and stem cells compared to simultaneous treatment or either drug alone|
|Humanigen Inc., of Burlingame, Calif.||GM-CSF k/o CART19||CAR T with granulocyte-macrophage colony-stimulating factor knocked out||Preclinical (acute lymphoblastic leukemia)||In a xenograft model for relapsed acute lymphoblastic leukemia, therapy improved overall survival compared to wildtype CART19|
|Iaso Biotherapeutics Co. Ltd., of Nanjing, China, and Innovent Biologics Inc., of Suzhou, China||CT-103A||Anti-BCMA CAR T||Relapsed/refractory multiple myeloma||Objective response rate was 100% in 17 evaluable patients in a phase I study; 70.6% of patients achieved a best response of stringent complete or complete response and 88.2% achieved a best response of very good partial response or better|
|Medigene AG, of Munich/Martinsried, Germany||DC vaccine||Dendritic cell vaccine||Acute myeloid leukemia||1-year interim assessment of phase I/II trial showed that, upon in vitro stimulation with WT-1 or PRAME, T cells from peripheral blood of 75% (6 of 8) of relapsing patients were capable of producing the pro-inflammatory cytokine IFNgamma, while such a response was detected in only 25% (3 of 12) of the patients in remission|
For more information about individual companies and/or products, see Cortellis.